Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.

Saved in:
Bibliographic Details
Title: Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.
Authors: van der Wel JWT; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Ernst SM; Department of Pulmonary Diseases, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands., Jebbink M; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands., Badrising SK; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Steinbusch LC; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, the Netherlands., Ruiter G; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Theelen WSME; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Veggel BAMH; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pulmonary Diseases, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands., Smit J; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Dingemans AM; Department of Pulmonary Diseases, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands., Paats MS; Department of Pulmonary Diseases, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands., Dubbink HJ; Department of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands., Hashemi SMS; Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, the Netherlands., Radonic T; Department of Pathology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, the Netherlands., Cohen D; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands., van der Wekken AJ; Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Ter Elst A; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Timens W; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Hendriks LE; Department of Pulmonary Diseases, GROW - Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands., Speel EJM; Department of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Pathology, GROW - Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands., Disselhorst MMJ; Department of Pulmonary Diseases, Northwest Clinics, Alkmaar, the Netherlands., Welling A; Department of Pulmonary Diseases, Northwest Clinics, Alkmaar, the Netherlands., van der Meer F; Department of Pulmonary Diseases, Diakonessenhuis, Utrecht, the Netherlands., Bosch LJW; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Monkhorst K; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Boelens MC; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, the Netherlands., de Langen AJ; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: j.d.langen@nki.nl.
Source: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2025 Nov; Vol. 209, pp. 108783. Date of Electronic Publication: 2025 Sep 28.
Publication Type: Clinical Trial; Journal Article; Multicenter Study
Journal Info: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1872-8332
DOI:10.1016/j.lungcan.2025.108783